Becton Dickinson and Co (BDX) Shares Sold by B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund
B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund cut its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 55.7% in the 2nd quarter, Holdings Channel reports. The firm owned 1,345 shares of the medical instruments supplier’s stock after selling 1,690 shares during the quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Becton Dickinson and were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also made changes to their positions in the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at $105,000. Bartlett & Co. LLC increased its position in shares of Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares during the last quarter. Bridgeworth LLC purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at $131,000. BDO Wealth Advisors LLC increased its position in shares of Becton Dickinson and by 361.6% during the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after purchasing an additional 452 shares during the last quarter. Finally, Kaizen Advisory LLC increased its position in shares of Becton Dickinson and by 155.9% during the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 371 shares during the last quarter. 86.96% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently issued reports on BDX shares. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. KeyCorp reaffirmed a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 target price for the company in a research report on Thursday, June 21st. Citigroup lifted their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $251.64.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter last year, the firm posted $2.46 EPS. The firm’s revenue for the quarter was up 41.0% on a year-over-year basis. sell-side analysts expect that Becton Dickinson and Co will post 11.01 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 31.65%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.